Skip to main content
Figure 4 | Genetic Vaccines and Therapy

Figure 4

From: Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming

Figure 4

CD4+/CD8+ cell numbers and expression of CD44hiCD62Llo or CD44lo/CD62Lhi in the lungs of mice from the various experimental groups. (A) CD4+/CD8+ cell numbers in the lungs. (B) Representative cell gating data showing the separation of effector cell populations. (C) CD44lo/CD62Lhi expression on CD4+ and CD8+ lung cells. (D) CD44hi/CD62Llo expression on CD4+ and CD8+ lung cells. Groups of 7 mice were immunized according table I and 15 days after the last immunization, they were challenged with H37Rv. After 30 days of infection, the lungs were removed and analyzed by flow cytometry for cell population and expression of cell surface molecules. (A) All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65. (C) All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGin, BCGsc and DNA-HSP65.** BCGin/DNA vs BCGin. (D) All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGsc, BCGin, DNA-HSP65 and BCGsc/DNA. ** BCGin/DNA vs BCGsc. Bars represent the mean ± standard deviation. p < 0.05 was considered significant. Data are representative of two experiments.

Back to article page